✦ LIBER ✦

Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial

✍ Scribed by Zaher K. Otrock; Sami T. Azar; Wael A. Shamseddeen; Dany Habr; Adlette Inati; Suzane Koussa; Rami A. R. Mahfouz; Ali T. Taher

Publisher: Springer
Year: 2006
Tongue: English
Weight: 93 KB
Volume: 85
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-006-0136-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Zoledronic Acid in the Treatment of Thalassemia-Associated Osteopenia

✍ C. P. Gilfillan; B. J. S. Strauss; C. P. Rodda; D. K. Bowden; A.-M. Kean; M. Oba 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 120 KB

A multicenter phase II trial of domestic

A multicenter phase II trial of domestic product of zoledronic acid in the treatment of malignant hypercalcemia

✍ Lijun Di; Jun Ren; Ying Yan 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 206 KB

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a